[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
[2] Ng WT, Yau TK, Yung RW, Sze WM, Tsang AH, Law AL, Lee AW. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer, 2005, 113(6): 998-1001.
[3] Sun LM, Epplein M, Li CI, Vaughan TL, Weiss NS. Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002. Am J Epidemiol, 2005, 162(12): 1174-1178.
[4] Simons MJ, Day NE, Wee GB, Shanmugaratnam K, Ho HC, Wong SH, Ti TK, Yong NK, Darmalingam S, De Thé G. Nasopharyngeal carcinoma V: immunogenetic studies of Southeast Asian ethnic groups with high and low risk for the tumor. Cancer Res, 1974, 34(5): 1192-1195.
[5] Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ. HLA and nasopharyngeal carcinoma in Chinese--a further study. Int J Cancer, 1983, 32(2): 171-176.
[6] Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, Mack SJ, Chen IH, Hsu MM, Yang CS, Brinton LA, Levine PH, Erlich HA. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst, 2002, 94(23): 1780-1789.
[7] Tang M, Zeng Y, Poisson A, Marti D, Guan L, Zheng Y, Deng H, Liao J, Guo X, Sun S, Nelson G, de Thé G, Winkler CA, O'Brien SJ, Carrington M, Gao X. Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population. Genes Immun, 2010, 11(4): 334-342.
[8] Lu SJ, Day NE, Degos L, Lepage V, Wang PC, Chan SH, Simons M, McKnight B, Easton D, Zeng Y. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA regions. Nature, 1990, 346(6283): 470-471.
[9] 曾毅. 遗传因素、环境因素及EB病毒在鼻咽癌发生中作用的研究. 中国肿瘤, 1995, 4(3): 24-25.
[10] Liu ZS, Liu YF, Zeng Y. Synergistic effect of Epstein-Barr virus and tumor promoters on induction of lymphoma and carcinoma in nude mice. J Cancer Res Clin Oncol, 1998, 124(10): 541-548.
[11] Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol, 2006, 67(11): 847-862.
[12] Heemels MT, Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem, 1995, 64: 463-491.
[13] Adams SD, Barracchini KC, Simonis TB, Stroncek D, Marincola FM. High throughput HLA sequence-based typing (SBT) utilizing the ABI Prism 3700 DNA Analyzer. Tumori, 2001, 87(2): S40-S43.
[14] Cox ST, McWhinnie AJ, Robinson J, Marsh SGE, Parham P, Madrigal JA, Little AM. Cloning and sequencing full-length HLA-B and -C genes. Tissue Antigens, 2003, 61(1): 20-48.
[15] 闫春霞, 宋艳萍, 赖淑苹, 赖江华, 张洪波, 赵君海, 李生斌. 应用PCR-SSOP技术研究中国汉族、维吾尔族HLA-A基因座基因多态性. 遗传学报, 2002, 29(5): 384-389.
[16] Baines M, Ebringer A. HLA and disease. Mol Aspects Med, 1992, 13(4): 263-378.
[17] Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors. Semin Cancer Biol, 2012, 22(2): 107-116.
[18] Zhao ML, Cai HB, Li X, Zheng H, Yang XX, Fang WY, Zhang LC, Wei GG, Li M, Yao KT, Li X. Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese. J Transl Med, 2012, 10(1): 57.
[19] Ghandri N, Gabbouj S, Farhat K, Bouaouina N, Abdelaziz H, Nouri A, Chouchane L, Hassen E. Association of HLA-G polymorphisms with nasopharyngeal carcinoma risk and clinical outcome. Hum Immu-nol, 2011, 72(2): 150-158.
[20] Lind C, Ferriola D, Mackiewicz K, Heron S, Rogers M, Slavich L, Walker R, Hsiao T, McLaughlin L, D'Arcy M, Gai X, Goodridge D, Say
